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Small moleculesmodulate the activity of G protein-coupled receptors in a number of different ways leading to
distinct signaling outcomes, but the mechanisms behind this modulation remain unclear. In this issue of
Structure, Zocher et al. have used dynamic single-molecule force spectroscopy to study this question by
examining global thermodynamic properties of b2AR in the presence of different ligands.G protein-coupled receptors (GPCRs) are
a family of seven-transmembrane helix
proteins found in almost all eukaryotic
organisms that respond to a wide variety
of external sensory or endogenous sig-
nals. Ligand binding is translated into
conformational changes in the receptor
that result in activation of intracellular G
proteins, GPCR kinases, and arrestins,
which, in turn, modulate the activity of
downstream effectors inside the cell.
GPCRs are essential in cell physiology,
and their malfunction is commonly trans-
lated into pathological outcomes. As a
result, GPCRs constitute one of the most
important pharmaceutical targets.
The beta 2 adrenergic receptor (b2AR)
is one of the most extensively character-
ized GPCR and serves as a model system
for understanding general principles of
GPCR structure, signaling, and physi-
ology. This receptor has a rich pharma-
cology with ligands that increase the level
of basal activity toward the G protein
(partial and full agonists), decrease it
(inverse agonists), or block the receptor
without changing its activity (neutral
antagonists). In addition, in recent years,
some ligands have been found to modu-
late separately the different cellular path-
ways that can be activated by a GPCR,
receiving the name of biased agonists.
For instance, bucindolol, carvedilol, feno-
terol, and terbutaline have been shown to
display a bias toward beta-arrestin-medi-
ated signaling pathways.
Ligands modulate the function of
GPCRs by stabilizing specific conforma-
tions of the receptor, but the details of
this general mechanism are not yet com-pletely understood. The available crystal
structures of GPCR-ligand complexes
represent only snapshots generally ob-
tained using heavily engineered proteins.
For this reason, complementary data,
particularly obtained through spectro-
scopic methods, are key to unravel the
dynamic aspects of GPCRs activation.
The b2AR has been extensively used
to measure ligand-induced conforma-
tional changes to different degrees of
spatial and temporal resolution using a
wide variety of spectroscopy techniques,
mostly in detergent-solubilized receptors,
but also in living cells. Single molecule
spectroscopy experiments (Bockenhauer
et al., 2011) have demonstrated that, even
in the absence of ligands, the receptor
exists in equilibrium between a number
of discrete conformational states. Agonist
binding (or other factors, e.g., oligomeri-
zation) promotes activation by shifting
this equilibrium toward the active states,
although binding of G protein is required
for their full stabilization. Fluorescence
resonance energy transfer (FRET) experi-
ments in living cells have permitted anal-
ysis of the individual steps of the activa-
tion pathway, from ligand binding to the
production of second messengers (Lohse
et al., 2009). This technique is sensitive
enough to detect, for instance, distinct
conformational changes induced by epi-
nephrine and norepinephrine and allows
the calculation of activation kinetics
(Reiner et al., 2010). Higher spatial reso-
lution can be obtained by measuring
fluorescence intensity and kinetics (see
Kobilka, 2007 for a review). These experi-
ments can discriminate between confor-Structure 20, August 8, 2012 ªmational changes induced by agonists or
partial agonists (Swaminath et al., 2005)
or even find specific switches that are
triggered during activation (Yao et al.,
2006). Finally, NMR spectroscopy has
shown that there is a conformational
coupling between the extracellular re-
gions of the receptor and the orthosteric
binding site (Bokoch et al., 2010) and
has allowed us to propose specific con-
formational changes involved in biased
signaling (Liu et al., 2012).
Spectroscopy measurements can be
complemented by data that record struc-
ture-related information from the whole
system simultaneously. For instance,
quantitative mass spectrometry studies,
which measure the reactivity of Cys and
Lys to a labeling agent upon activation
by different ligands, have found that
ligands induce a significant variability in
receptor conformations (Kahsai et al.,
2011). Along this line, this issue of Struc-
ture presents a work where dynamic
single-molecule force spectroscopy is
used to study global thermodynamic
properties of b2AR in the presence of
different ligands (Zocher et al., 2012).
In these experiments, liposomes con-
taining the receptor are attached to a
mica surface. The tip of the atomic force
microscope captures the N- or C terminus
of a single molecule of the receptor and
pulls it at a constant velocity, which
results in the sequential unfolding of
secondary structural elements. The mi-
croscope records the force during the
pulling, and the force-distance profiles
allow determining a number of thermody-
namic parameters related to the stability2012 Elsevier Ltd All rights reserved 1289
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paring these parameters obtained in the
presence of three agonists (adrenaline,
BI-167107, and THRX-144877), the in-
verse agonist carazolol, and the neutral
antagonist alprenolol, the authors have
been able to observe which regions of
the receptor are stabilized in the presence
of each type of ligand.
All the experiments consistently detect
a series of structural elements that un-
fold together. In some cases, these ele-
ments are part of a transmembrane helix,
and in other cases, they are composed
by several transmembrane segments
and loops. One of these ‘‘unfolding struc-
tural elements’’ is roughly composed of
TM3-TM4-TM5, and is labeled as ‘‘core
segment’’.
In the absence of ligand, the core
segment has a relatively high flexibility
that allows the receptor to sample many
conformational states, possibly contrib-
uting to basal activity of b2AR. This
heterogeneity agrees with single-mole-
cule fluorescence spectroscopy data
(Bockenhauer et al., 2011).
All ligands seem to bind ‘‘loosely,’’
without mediating strong stabilizing inter-
helical interactions. Agonists and inverse
agonists increase the conformational vari-
ability of the core segment. In the case of
agonists, this would allow this region to
sample the active state conformations
more efficiently. But, surprisingly, the in-
verse agonist carazolol is the ligand that
introduces most changes in the ther-
modynamic properties of the structural
elements: in TM1, in the core segment,
and in TM6-TM7-hx8. A possible explana-
tion is that while agonists would stabilize
conformations that are to some extent
already sampled by the empty receptor,1290 Structure 20, August 8, 2012 ª2012 Elsinverse agonists must stabilize a different
conformation that is not part of conforma-
tional space of the empty receptor. FRET
studies in b2AR reconstituted in lipid vesi-
cles have shown that carazolol (but not
alprenolol, see below) promotes the for-
mation of high-order oligomers (Fung
et al., 2009). Thus, the authors propose
that the extensive changes in the confor-
mational variability of the core segment
induced by carazolol may be related to
oligomerization, which remains to be con-
firmed by further experiments.
The neutral antagonist alprenolol only
stabilizes part of TM1. This is a surprising
and counterintuitive effect, as this ligand
does not interact directly with this region
(Wacker et al., 2010). The authors suggest
that these modest changes support the
idea that neutral antagonists simply block
the receptor without changing substan-
tially its thermodynamic properties. It is
difficult to visualize in structural terms
how alprenolol and carazolol can result
in such dramatically different effects in
receptor stability and tendency to oligo-
merize (Fung et al., 2009). Their binding
poses are very similar, stabilizing compa-
rable helix-helix interactions and differing
only in the interaction with TM5. Thus,
this may be an illustration of how crystal
structures do not reflect the dynamic
aspects of a protein. For instance, it is
possible that the higher off-rate of alpre-
nolol compared with carazolol (which, of
course, cannot be accounted for in a
crystal structure) results in the overall
weaker interactions observed in this work.
In summary, single-molecule force
spectroscopy provides a way of esti-
mating thermodynamic properties of
ligand-bound GPCRs. While it may be dif-
ficult to assess the relevance of thermo-evier Ltd All rights reserveddynamic parameters when the receptor
has been mostly unfolded, this work
convincingly shows that the technique
can measure differences between ligands
of different efficacies and how they af-
fect specific structural elements of the
receptor.
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